Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: A prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 842-850

  Ghesquieres H ^a   Ferlay, C ^a   Sebban, C ^a   Perol, D ^a   Bosly, A ^b   Casasnovas, O ^c   Reman, O ^d   Coiffier, B ^e   Tilly, H ^f   Morel, P ^g   van den Neste, E ^h   Colin, P ⁱ   Haioun, C ^j   Biron, P ^a   Blay, J Y ^a  

^a UNIVERSITÉ DE LYON   (France)

^b UCL Mont Godine   (Belgium)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g Hopital Schaffner   (France)

^h Hôpital Saint Luc   (Belgium)

ⁱ Clinique Courlancy   (France)

^j HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

CNS lymphoma; Methotrexate; Neurotoxicity; Radiotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; METHYLPREDNISOLONE; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 77951948588     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp529     Document Type: Article

References (30)

1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006; 24: 1281-1288.
2. Blay JY, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864-871.
3. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-3150.
4. Bessell EM, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20: 231-236.
5. DeAngelis LM, Seiferheld W, Schold SC et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643-4648.
6. Ferreri AJ, Dell'Oro S, Foppoli M et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006; 66: 1435-1438.
7. Gavrilovic IT, Hormigo A, Yahalom J et al. Long-term follow-up of high-dosemethotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24: 4570-4574.
8. Kiewe P, Fischer L, Martus P et al. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer 2008; 112: 1812-1820.
9. O'Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519-526.
10. Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005; 64: 69-74.
11. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 4483-4488.
12. Blay JY, Bouhour D, Carrie C et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995; 86: 2922-2929.
13. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
14. Kaplan RS, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-272.
16. Korfel A, Martus P, Nowrousian MR et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 2005; 128: 177-183.
17. Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25: 2295-2305.
18. Ghesquières H, Sunyach MP, Drouet Y et al. Long-term follow-up of 132 immunocompetent primary central nervous system lymphomas treated at Leon Berard Cancer Centre: proposition of a new prognostic model. Blood 2008; 110: (Abstr 521).
19. Bessell EM, Graus F, Lopez-Guillermo A et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2001; 50: 457-464.
20. Jahnke K, Hummel M, Korfel A et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 2006; 24: 4754-4757.
21. Ferreri AJ, Guerra E, Regazzi M et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90: 353-358.
22. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46: 435-439.
23. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726-2731.
24. Omuro AM, Taillandier L, Chinot O et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007; 85: 207-211.
25. Illerhaus G, Marks R, Muller F et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20: 319-325.
26. Soussain C, Hoang-Xuan K, Taillandier L et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26: 2512-2518.
27. Illerhaus G, Muller F, Feuerhake F et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93: 147-148.
28. Ferreri AJ, Foppoli M, martelli M et al. Randomized phase II trial of primary chemotherapy with high dose methotrexate alone or associated with high dose cytarabine for patients with primary CNS lymphomas. Ann Oncol 2008; 19: (Suppl 4) (Abstr 65).
29. Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730-4735.
30. Correa DD, Maron L, Harder H et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18: 1145-1151.